6-(2-bromoeth-1-oxy)-3-phenyl-7-propylbenzisoxazole | 194982-37-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并异恶唑
• 英文名称: 6-(2-bromoeth-1-oxy)-3-phenyl-7-propylbenzisoxazole
• 英文别名: 6-(2-Bromoethoxy)-3-phenyl-7-propyl-1,2-benzoxazole
• CAS: 194982-37-1
• 化学式: C₁₈H₁₈BrNO₂
• 分子量: 360.25
• InChiKey: XQQWELYBYHUWBA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  35.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-(2-bromoeth-1-oxy)-3-phenyl-7-propylbenzisoxazole 、 alkaline earth salt of/the/ methylsulfuric acid 在 caesium carbonate 、 氢氧化钾 作用下， 以 甲醇 为溶剂， 生成 3-{4-[2-(3-Phenyl-7-propyl-benzo[d]isoxazol-6-yloxy)-ethoxy]-phenyl}-propionic acid
  参考文献：
  名称：

  Amphipathic 3-Phenyl-7-propylbenzisoxazoles; human pPaR γ, δ and α agonists

  摘要：

  A series of amphipathic 3-phenylbenzisoxazoles were found to be potent agonists of human PPARalpha, gamma and delta. The optimization of acid proximal structure for in vitro and in vivo potency is described. Results of po dosed efficacy studies in the db/db mouse model of type 2 diabetes showed efficacy equal or superior to Rosiglitazone in correcting hyperglycemia and hyper-triglyceridemia. Good functional receptor selectivity for PPARalpha and gamma over PPARdelta can be obtained. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)01029-6
• 作为产物：
  描述：

  4-丙烯氧基-2-羟基二苯甲酮 在 palladium on activated charcoal 盐酸羟胺 、 氢气 、 乙酸酐 、 caesium carbonate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 、 邻二氯苯 为溶剂， 生成 6-(2-bromoeth-1-oxy)-3-phenyl-7-propylbenzisoxazole
  参考文献：
  名称：

  Amphipathic 3-Phenyl-7-propylbenzisoxazoles; human pPaR γ, δ and α agonists

  摘要：

  A series of amphipathic 3-phenylbenzisoxazoles were found to be potent agonists of human PPARalpha, gamma and delta. The optimization of acid proximal structure for in vitro and in vivo potency is described. Results of po dosed efficacy studies in the db/db mouse model of type 2 diabetes showed efficacy equal or superior to Rosiglitazone in correcting hyperglycemia and hyper-triglyceridemia. Good functional receptor selectivity for PPARalpha and gamma over PPARdelta can be obtained. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)01029-6

文献信息

• [EN] HETEROCYCLIC DERIVATIVES AS ANTIDIABETIC AND ANTIOBESITY AGENTS<br/>[FR] DERIVES HETEROCYCLIQUES UTILISES COMME AGENTS CONTRE LE DIABETE ET CONTRE L'OBESITE
  申请人：MERCK & CO., INC.

  公开号：WO1997028137A1

  公开（公告）日：1997-08-07

  (EN) The instant invention is concerned with acetylphenols which are useful as antiobesity and antidiabetic compounds. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering or modulating triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for increasing gut motility or for treating atherosclerosis are also disclosed.(FR) L'invention concerne des acétylphénols utiles comme composés contre l'obésité et contre le diabète. Sont également décrites des compositions et des méthodes d'utilisation de ces composés destinées au traitement du diabète et de l'obésité, servant à abaisser ou à moduler les taux de triglycérides et de cholestérol ou à élever les taux de lipoprotéines haute densité ou à accélérer le transit intestinal, ou à traiter l'athérosclérose.

  该发明涉及用作抗肥胖和抗糖尿病化合物的乙酰苯酚。还公开了用于治疗糖尿病和肥胖症的化合物的组合物和使用方法，用于降低或调节甘油三酯水平和胆固醇水平或提高高密度脂蛋白水平或增加肠道运动性或治疗动脉粥样硬化。
• US6090836
  申请人：——

  公开号：——

  公开（公告）日：——
• HETEROCYCLIC DERIVATIVES AS ANTIDIABETIC AND ANTIOBESITY AGENTS
  申请人：MERCK & CO., INC.

  公开号：EP0882029A1

  公开（公告）日：1998-12-09
• US6090836A
  申请人：——

  公开号：US6090836A

  公开（公告）日：2000-07-18
• Amphipathic 3-Phenyl-7-propylbenzisoxazoles; human pPaR γ, δ and α agonists
  作者：Alan D Adams、Winston Yuen、Zao Hu、Conrad Santini、A.Brian Jones、Karen L MacNaul、Joel P Berger、Thomas W Doebber、David E Moller

  DOI：10.1016/s0960-894x(02)01029-6

  日期：2003.3

  A series of amphipathic 3-phenylbenzisoxazoles were found to be potent agonists of human PPARalpha, gamma and delta. The optimization of acid proximal structure for in vitro and in vivo potency is described. Results of po dosed efficacy studies in the db/db mouse model of type 2 diabetes showed efficacy equal or superior to Rosiglitazone in correcting hyperglycemia and hyper-triglyceridemia. Good functional receptor selectivity for PPARalpha and gamma over PPARdelta can be obtained. (C) 2003 Elsevier Science Ltd. All rights reserved.